Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2315-2320

  Sloan, Derek J ^a,b,c   Corbett, Elizabeth L ^a,b,d   Butterworth, Anthony E ^b,d   Mwandumba, Henry C ^a,b   Khoo, Saye H ^c   Mdolo, Aaron ^b   Shani, Doris ^b   Kamdolozi, Mercy ^b   Allen, Jenny ^e   Mitchison, Denis A ^f   Coleman, David J ^f   Davies, Geraint R ^c  

^a MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^b UNIVERSITY OF MALAWI   (Malawi)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CARBENDAZIM;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SCREENING; FEMALE; FUNGAL CONTAMINATION; FUNGAL STRAIN; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAWI; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RESOURCE ALLOCATION; RISK FACTOR; RISK REDUCTION; SERIAL SPUTUM COLONY COUNTING; SPUTUM ANALYSIS; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTIFUNGAL AGENTS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; COHORT STUDIES; CULTURE MEDIA; DEVELOPING COUNTRIES; DRUG MONITORING; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALAWI; MALE; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENTS; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84862746408     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00043-12     Document Type: Article

References (25)

1. Block ER, Bennett JE. 1973. Stability of amphotericin B in infusion bottles. Antimicrob. Agents Chemother. 4:648-649.
2. Brindle R, Odhiambo J, Mitchison D. 2001. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm. Med. 1:2. doi:10.1186/1471-2466-1-2.
3. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26:874-877.
4. Conde MB, et al. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
5. Davies GR, Brindle R, Khoo SH, Aarons LJ. 2006. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob. Agents Chemother. 50:3154-3156.
6. Davies GR, Khoo SH, Aarons LJ. 2006. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J. Antimicrob. Chemother. 58:594-600.
7. Diacon AH, et al. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
8. Grandjean L, et al. 2008. Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation. J. Clin. Microbiol. 46:2339-2344.
9. International Union Against Tuberculosis and Lung Diseases. 2000. Technical guide: sputum examination for tuberculosis by direct microscopy in low income countries. International Union Against Tuberculosis and Lung Diseases, Paris, France. http://www.tbrieder.org/publications/books-english/microscopy. pdf.
10. Kennedy N, et al. 1996. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin. Infect. Dis. 22:827-833.
11. Kennedy N, et al. 1993. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am. Rev. Respir. Dis. 148:1547-1551.
12. Ministry of Health, Malawi. 2011. Clinical management of HIV in children and adults, 1st ed. Ministry of Health, Malawi. http://www.who.int/hiv/pub/ guidelines/malawi-art.pdf.
13. Mitchison DA. 2006. Clinical development of anti-tuberculosis drugs. J. Antimicrob. Chemother. 58:494-495.
14. Mitchison DA, Allen BW, Carrol L, Dickinson JM, Aber VR. 1972. A selective oleic acid albumin agar medium for tubercle bacilli. J. Med. Microbiol. 5:165-175.
15. Mitchison DA, Allen BW, Lambert RA. 1973. Selective media in the isolation of tubercle bacilli from tissues. J. Clin. Pathol. 26:250-252.
16. National Statistics Office of Malawi. 2005. Second integrated household survey 2004-2005. National Statistics Office, Zomba, Malawi. http://siteresources.worldbank.org/INTLSMS/Resources/3358986-1181743055198/ 3877319-1181928149600/IHS2-Basic-Information2.pdf.
17. Peres RL, et al. 2009. Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. Int. J. Tuberc. Lung Dis. 13:1572-1575.
18. Phillips P, Fielding K. 2008. Surrogate markers for poor outcome to treatment for tuberculosis: results from extensive multi-trial analysis. Int. J. Tuberc. Lung Dis. 12:S146-S147.
19. Rothlauf MV, Brown GL, Blair EB. 1981. Isolation of mycobacteria from undecontaminated specimens with selective 7H10 medium. J. Clin. Microbiol. 13:76-79.
20. Rustomjee R, et al. 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:2831-2835.
21. Rustomjee R, et al. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
22. Salomon JA, et al. 2006. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med. 3:e273. doi:10.1371/journal.pmed. 0030273.
23. Sloan DJ, Davies GR. 2011. Anti-tuberculous chemotherapy: serial sputum colony counting in drug development, p 277-324. In Donald PR, Van Helden PD (ed), Progress in respiratory research, vol 40. Karger, Basel, Switzerland.
24. Wang X, et al. 2012. Response of soil bacterial community to repeated applications of carbendazim. Ecotoxicol. Environ. Saf. 75:33-39.
25. World Health Organization. 2009. Global tuberculosis control 2009. Epidemiology, strategy, financing. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/2009/en/index. html.